Oxyrane raises $26.5M in a series D

Oxyrane U.K. Ltd. (Manchester, U.K.) raised $26.5 million in a series D round. New investors Forbion Capital Partners and Morningside Group joined existing investor New Science Ventures.

Oxyrane is developing enzyme replacement therapies to treat lysosomal storage disorders, with a product for Pompe's disease in preclinical testing. ...